Advertisement
EDIT vs SLDB
Which Stock Would AI Choose? Editas Medicine (EDIT) vs. Solid Biosciences (SLDB) Stock Comparison
Key Takeaways
- EDIT is a clinical-stage gene-editing company whose lead candidate, EDIT-401, recently cleared Australian regulators to begin first-in-human dosing for a cholesterol disorder.
- SLDB is advancing SGT-003, a gene therapy for Duchenne muscular dystrophy (DMD), through an ongoing Phase 3 registration trial with a broader rare-disease pipeline.
- Both companies are pre-revenue and loss-making, but SLDB carries a materially larger cash position, giving it a longer runway into 2028.
- Analyst consensus is more uniformly bullish on SLDB (a "Strong Buy" consensus), while EDIT shows a more mixed mix of ratings.
- The two names represent different risk profiles: EDIT is an earlier-stage, high-beta turnaround story, while SLDB is further along with late-stage clinical momentum.
- For ongoing coverage, explore EDIT Major News and EDIT Today's Price Move, plus SLDB Major News and SLDB Today's Price Move.
- To see how automated strategies are positioning across these and other names, explore the Trending AI Robots.
Introduction
This stock comparison examines two clinical-stage biotechnology companies whose fortunes hinge on single lead programs. EDIT (Editas Medicine) is betting on in vivo gene editing for cardiovascular disease, while SLDB (Solid Biosciences) is advancing a gene therapy for a rare neuromuscular disorder. Because neither company yet generates meaningful product revenue, relative performance is driven by clinical milestones, regulatory clearances, cash runways, and analyst sentiment rather than fundamentals. Growth-oriented and healthcare-sector investors, as well as traders watching momentum and volatility in small-cap biotech, may find this head-to-head useful for understanding how market positioning and risk profiles differ between two superficially similar "pipeline" stories.
EDIT Overview and Recent Performance
Editas Medicine is a pioneering genome-editing company built around CRISPR/Cas9 (a gene-editing technology that uses a guide molecule to cut DNA at precise locations). After discontinuing its reni-cel program in late 2024 and reducing its workforce, EDIT refocused on EDIT-401, an experimental one-time, in vivo therapy that edits the LDLR gene to durably lower LDL ("bad") cholesterol in patients with heterozygous familial hypercholesterolemia (HeFH), an inherited condition that sharply raises cardiovascular risk.
Recent weeks brought a key catalyst: Australian regulators cleared the Phase 1/2 "Strive" trial of EDIT-401, allowing first-in-human dosing. Preclinical data showed roughly 90% or greater reductions in LDL cholesterol and other atherogenic lipoproteins in non-human primates, with durability extending toward ten months. The news prompted analyst upgrades, including a Wells Fargo upgrade to "Overweight" with a $6 price target. The stock has shown notable volatility and a strong year-to-date advance, though it trades well below its multi-year highs. Sentiment remains tied to early safety data expected in early 2027 and top-line results later that year.
SLDB Overview and Recent Performance
Solid Biosciences is a precision genetic-medicine company focused on neuromuscular and cardiac diseases. Its lead asset, SGT-003, is an investigational gene therapy for Duchenne muscular dystrophy (DMD), a progressive muscle-wasting disorder. SLDB has already dosed dozens of participants in its Phase 1/2 INSPIRE DUCHENNE study, reporting generally well-tolerated safety data and encouraging microdystrophin expression, and has initiated the Phase 3 IMPACT DUCHENNE registration trial. The company is also developing earlier-stage programs for Friedreich's ataxia and certain genetic cardiac conditions.
In recent months, SLDB has attracted a wave of new coverage, including an RBC Capital initiation at "Outperform" and a UBS initiation at "Buy," contributing to a "Strong Buy" consensus with an average price target well above the current share price. The company reported no revenue and a widening quarterly net loss, but its cash position is viewed as sufficient to fund operations into 2028. Performance has been choppy, with sharp short-term swings alongside a strong longer-horizon advance as the Duchenne program progressed.
Trending AI Robots
Tickeron's Trending AI Robots page showcases a curated selection of automated trading strategies drawn from a much larger universe of AI-powered bots that monitor thousands of tickers. Rather than listing every available system, the page highlights only those whose recent performance and configuration align with current market conditions. The featured bots span a wide range of trading styles, strategies, timeframes, and statistical profiles, and each trades a distinct set of tickers — so the same bot may behave differently across names like EDIT and SLDB. Investors and traders interested in data-driven, rules-based approaches can explore the Trending AI Robots to compare performance metrics and identify strategies suited to their objectives.
Head-to-Head Comparison
The two companies differ most clearly in stage of development and therapeutic focus. SLDB is further along, with a Phase 3 registration study underway and a broader, multi-asset pipeline, whereas EDIT is only now entering first-in-human testing for a single lead candidate after a strategic reset. On the financial side, SLDB holds a larger cash balance and a longer runway, reducing near-term dilution risk relative to EDIT, whose smaller reserve still extends into the second half of 2028.
Momentum and sentiment also diverge. EDIT has benefited from a strong recent catalyst cycle and higher volatility (a beta near 2.0), while SLDB enjoys a more uniformly positive analyst consensus but faces the execution risk inherent in late-stage gene-therapy trials and a competitive DMD landscape. Sector exposure overlaps in gene-based medicine, but EDIT leans toward large cardiovascular indications and SLDB toward rare neuromuscular and cardiac diseases. In short, EDIT offers higher potential upside with greater early-stage uncertainty, while SLDB presents a more de-risked but still pre-revenue profile.
Tickeron AI Verdict
Based on observable factors such as trend consistency, relative stability, catalyst visibility, and financial positioning, Tickeron's AI would likely lean toward SLDB at present. The company's more advanced clinical stage, larger cash runway, and broader analyst support suggest a comparatively steadier risk profile. However, EDIT carries meaningful momentum and a fresh catalyst cycle that could attract trend-following and event-driven strategies if early clinical data land favorably. The verdict is therefore probabilistic rather than definitive, reflecting the different trade-offs each name presents rather than a guaranteed outcome.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is EDIT is a Hold and SLDB is a StrongBuy.
Aroon Indicator for EDIT shows an upward move is likely
EDIT's Aroon Indicator triggered a bullish signal on November 11, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 154 similar instances where the Aroon Indicator showed a similar pattern. In 128 of the 154 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at 83%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
Following a +7.84% 3-day Advance, the price is estimated to grow further. Considering data from situations where EDIT advanced for three days, in 182 of 227 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on EDIT as a result. In 78 of 84 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
The Moving Average Convergence Divergence Histogram (MACD) for EDIT turned negative on November 11, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 49 similar instances when the indicator turned negative. In 44 of the 49 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
EDIT moved below its 50-day moving average on November 10, 2026 date and that indicates a change from an upward trend to a downward trend.
The 50-day moving average for EDIT moved below the 200-day moving average on November 09, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where EDIT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
EDIT broke above its upper Bollinger Band on October 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 30 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 53 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.749) is normal, around the industry mean (3.498). P/E Ratio (-3.894) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (5.855) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 71 (best 1 - 100 worst), indicating slightly worse than average price growth. EDIT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. EDIT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Momentum Indicator for SLDB turns positive, indicating new upward trend
SLDB saw its Momentum Indicator move above the 0 level on November 06, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 69 similar instances where the indicator turned positive. In 60 of the 69 cases, the stock moved higher in the following days. The odds of a move higher are at 87%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where SLDB's RSI Oscillator exited the oversold zone, 30 of 41 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 73%.
The Moving Average Convergence Divergence (MACD) for SLDB just turned positive on October 21, 2026. Looking at past instances where SLDB's MACD turned positive, the stock continued to rise in 35 of 44 cases over the following month. The odds of a continued upward trend are 80%.
SLDB moved above its 50-day moving average on November 11, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +8.26% 3-day Advance, the price is estimated to grow further. Considering data from situations where SLDB advanced for three days, in 200 of 252 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
Bearish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The 50-day moving average for SLDB moved below the 200-day moving average on November 04, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SLDB declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
SLDB broke above its upper Bollinger Band on November 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for SLDB entered a downward trend on October 26, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 20 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 30 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.889) is normal, around the industry mean (3.498). P/E Ratio (-3.487) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 48 (best 1 - 100 worst), indicating steady price growth. SLDB’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SLDB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
EDIT | SLDB | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 73 | 31 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 53 Fair valued | 30 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 99 | 98 | |
PRICE GROWTH RATING 1..100 | 71 | 48 | |
P/E GROWTH RATING 1..100 | 30 | 20 | |
SEASONALITY SCORE 1..100 | 85 | 75 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
SLDB's Valuation (30) in the Biotechnology industry is in the same range as EDIT (53). This means that SLDB’s stock grew similarly to EDIT’s over the last 12 months.
SLDB's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as EDIT (100). This means that SLDB’s stock grew similarly to EDIT’s over the last 12 months.
SLDB's SMR Rating (98) in the Biotechnology industry is in the same range as EDIT (99). This means that SLDB’s stock grew similarly to EDIT’s over the last 12 months.
SLDB's Price Growth Rating (48) in the Biotechnology industry is in the same range as EDIT (71). This means that SLDB’s stock grew similarly to EDIT’s over the last 12 months.
SLDB's P/E Growth Rating (20) in the Biotechnology industry is in the same range as EDIT (30). This means that SLDB’s stock grew similarly to EDIT’s over the last 12 months.
| EDIT | SLDB | |
|---|---|---|
| RSI ODDS (%) | N/A | 1 day ago 73% |
| Stochastic ODDS (%) | 1 day ago 77% | 1 day ago 87% |
| Momentum ODDS (%) | 1 day ago 90% | 1 day ago 87% |
| MACD ODDS (%) | 1 day ago 90% | 1 day ago 80% |
| TrendWeek ODDS (%) | 1 day ago 90% | 1 day ago 83% |
| TrendMonth ODDS (%) | 1 day ago 89% | 1 day ago 81% |
| Advances ODDS (%) | 3 days ago 80% | 1 day ago 79% |
| Declines ODDS (%) | 1 day ago 90% | 10 days ago 89% |
| BollingerBands ODDS (%) | 1 day ago 90% | 1 day ago 90% |
| Aroon ODDS (%) | 1 day ago 83% | 1 day ago 88% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
EDIT’s FA Score shows that 1 FA rating(s) are green while SLDB’s FA Score has 2 green FA rating(s).
- EDIT’s FA Score: 1 green, 4 red.
- SLDB’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
EDIT’s TA Score shows that 3 TA indicator(s) are bullish while SLDB’s TA Score has 4 bullish TA indicator(s).
- EDIT’s TA Score: 3 bullish, 6 bearish.
- SLDB’s TA Score: 4 bullish, 5 bearish.
Price Growth
EDIT (@Biotechnology) experienced а -12.50% price change this week, while SLDB (@Biotechnology) price change was +14.17% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -0.49%. For the same industry, the average monthly price growth was -6.84%, and the average quarterly price growth was -13.86%.
Reported Earning Dates
EDIT is expected to report earnings on Feb 25, 2027.
SLDB is expected to report earnings on Mar 16, 2027.
Industries' Descriptions
@Biotechnology (-0.49% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
EDIT and
Correlation & Price change
A.I.dvisor indicates that over the last year, EDIT has been closely correlated with BEAM. These tickers have moved in lockstep 67% of the time. This A.I.-generated data suggests there is a high statistical probability that if EDIT jumps, then BEAM could also see price increases.
| Ticker / NAME | Correlation To EDIT | 1D Price Change % | ||
|---|---|---|---|---|
| EDIT | 100% | -4.99% | ||
| BEAM - EDIT | 67% Closely correlated | +2.62% | ||
| CRSP - EDIT | 63% Loosely correlated | +1.33% | ||
| SLDB - EDIT | 62% Loosely correlated | +6.00% | ||
| PRME - EDIT | 61% Loosely correlated | +10.26% | ||
| VYGR - EDIT | 61% Loosely correlated | -3.56% | ||
More | ||||
SLDB and
Correlation & Price change
A.I.dvisor indicates that over the last year, SLDB has been loosely correlated with EDIT. These tickers have moved in lockstep 62% of the time. This A.I.-generated data suggests there is some statistical probability that if SLDB jumps, then EDIT could also see price increases.
| Ticker / NAME | Correlation To SLDB | 1D Price Change % | ||
|---|---|---|---|---|
| SLDB | 100% | +6.00% | ||
| EDIT - SLDB | 62% Loosely correlated | -4.99% | ||
| RCKT - SLDB | 54% Loosely correlated | +1.22% | ||
| BEAM - SLDB | 54% Loosely correlated | +2.62% | ||
| FDMT - SLDB | 54% Loosely correlated | +4.25% | ||
| TSHA - SLDB | 53% Loosely correlated | +0.12% | ||
More | ||||